Changes at Oncologix Reflect Med Tech Focus
by Sara Calabro
Med Tech Sentinel
Oncologix Tech (OCLG.OB), a former long-distance phone company that in January sold off its primary assets to focus exclusively on its medical device subsidiary, has taken steps to further its commitment to the sector.
For starters, it’s moving closer to the scientists and engineers working on its devices. The corporate offices will be moved from Grand Rapids, MI, to suburban Atlanta, in Suwanee, GA. That’s where the company’s R&D facility is, where development is taking place on Oncologix’s lead product, the Oncosphere System.
The Oncosphere System is a radiation therapy device being developed for the treatment of soft-tissue cancers. It is based on radioactive microparticles designed to deliver therapeutic radiation directly to a tumor site by introducing the microparticles into the artery that feeds the tumor tissue.
Oncologix also is consolidating the boards of its parent, Oncologix Tech (formerly BestNet Communications), and subsidiary, Oncologix Corporation. The goal is to create a greater wealth of medical device expertise on the board, a step further backed by the new appointment of Judy Lindstrom. Lindstrom has held senior management positions with several device companies, including Portland Orthopedics, Wright Medical Technology, Neovision and MicroAire Surgical Instruments.
The commitment to med tech is especially evident in the company’s decision about its chief executive. Andrew Green, who previously served as president and CEO of the Oncologix Corporation subsidiary, was named president and CEO of the whole company. Oncologix Tech/BestNet Communications’ former CEO, Stanley Scholz, will retain the chairman title under the new corporate structure.
Med Tech Sentinel is a regular contributor to BioHealth Investor
________________
Med Tech Sentinel
Oncologix Tech (OCLG.OB), a former long-distance phone company that in January sold off its primary assets to focus exclusively on its medical device subsidiary, has taken steps to further its commitment to the sector.
For starters, it’s moving closer to the scientists and engineers working on its devices. The corporate offices will be moved from Grand Rapids, MI, to suburban Atlanta, in Suwanee, GA. That’s where the company’s R&D facility is, where development is taking place on Oncologix’s lead product, the Oncosphere System.
The Oncosphere System is a radiation therapy device being developed for the treatment of soft-tissue cancers. It is based on radioactive microparticles designed to deliver therapeutic radiation directly to a tumor site by introducing the microparticles into the artery that feeds the tumor tissue.
Oncologix also is consolidating the boards of its parent, Oncologix Tech (formerly BestNet Communications), and subsidiary, Oncologix Corporation. The goal is to create a greater wealth of medical device expertise on the board, a step further backed by the new appointment of Judy Lindstrom. Lindstrom has held senior management positions with several device companies, including Portland Orthopedics, Wright Medical Technology, Neovision and MicroAire Surgical Instruments.
The commitment to med tech is especially evident in the company’s decision about its chief executive. Andrew Green, who previously served as president and CEO of the Oncologix Corporation subsidiary, was named president and CEO of the whole company. Oncologix Tech/BestNet Communications’ former CEO, Stanley Scholz, will retain the chairman title under the new corporate structure.
Med Tech Sentinel is a regular contributor to BioHealth Investor
________________
posted by Nico at
6:55 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home